Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Comparison of distinctive models for calculating an interlobar emphysema heterogeneity index in patients prior to endoscopic lung volume reduction.

Theilig D, Doellinger F, Poellinger A, Schreiter V, Neumann K, Hubner RH.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 1;12:1631-1640. doi: 10.2147/COPD.S133348. eCollection 2017.

2.

COPD in primary lung cancer patients: prevalence and mortality.

Ytterstad E, Moe PC, Hjalmarsen A.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 23;11:625-36. doi: 10.2147/COPD.S101183. eCollection 2016.

3.

Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors.

Binkley MS, Shrager JB, Chaudhuri A, Popat R, Maxim PG, Shultz DB, Diehn M, Loo BW Jr.

Radiat Oncol. 2016 Mar 15;11:40. doi: 10.1186/s13014-016-0616-8.

4.

The Impact of Homogeneous Versus Heterogeneous Emphysema on Dynamic Hyperinflation in Patients With Severe COPD Assessed for Lung Volume Reduction.

Boutou AK, Zoumot Z, Nair A, Davey C, Hansell DM, Jamurtas A, Polkey MI, Hopkinson NS.

COPD. 2015;12(6):598-605. doi: 10.3109/15412555.2015.1020149. Epub 2015 Sep 23.

5.

The complex care of severe emphysema: role of awake lung volume reduction surgery.

Pompeo E, Rogliani P, Palombi L, Orlandi A, Cristino B, Dauri M; Awake Thoracic Surgery Research Group (ATSRG).

Ann Transl Med. 2015 May;3(8):108. doi: 10.3978/j.issn.2305-5839.2015.04.17. Review.

6.

Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease.

Mizumori Y, Mochiduki Y, Nakahara Y, Kawamura T, Sasaki S, Morimoto A, Tsukamoto H.

J Thorac Dis. 2015 Mar;7(3):413-21. doi: 10.3978/j.issn.2072-1439.2015.01.10.

7.

A randomised trial of lung sealant versus medical therapy for advanced emphysema.

Come CE, Kramer MR, Dransfield MT, Abu-Hijleh M, Berkowitz D, Bezzi M, Bhatt SP, Boyd MB, Cases E, Chen AC, Cooper CB, Flandes J, Gildea T, Gotfried M, Hogarth DK, Kolandaivelu K, Leeds W, Liesching T, Marchetti N, Marquette C, Mularski RA, Pinto-Plata VM, Pritchett MA, Rafeq S, Rubio ER, Slebos DJ, Stratakos G, Sy A, Tsai LW, Wahidi M, Walsh J, Wells JM, Whitten PE, Yusen R, Zulueta JJ, Criner GJ, Washko GR.

Eur Respir J. 2015 Sep;46(3):651-62. doi: 10.1183/09031936.00205614. Epub 2015 Apr 2.

8.

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.

de-Torres JP, Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J, Campo A, Alcaide AB, García-Granero M, Celli BR, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91. doi: 10.1164/rccm.201407-1210OC.

9.

Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP-UP) study.

Valipour A, Herth FJ, Eberhardt R, Shah PL, Gupta A, Barry R, Henne E, Bandyopadhyay S, Snell G.

BMC Pulm Med. 2014 Dec 3;14:190. doi: 10.1186/1471-2466-14-190.

10.
11.

Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities.

Burgel PR, Paillasseur JL, Roche N.

Biomed Res Int. 2014;2014:420134. doi: 10.1155/2014/420134. Epub 2014 Feb 10. Review.

12.

Indacaterol: a comprehensive review.

Rossi A, Polese G.

Int J Chron Obstruct Pulmon Dis. 2013;8:353-63. doi: 10.2147/COPD.S21625. Epub 2013 Jul 25. Review.

13.

Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra.

de-Torres JP, Blanco D, Alcaide AB, Seijo LM, Bastarrika G, Pajares MJ, Muñoz-Barrutia A, Ortiz-de-Solorzano C, Pio R, Campo A, Montes U, Segura V, Pueyo J, Montuenga LM, Zulueta JJ.

PLoS One. 2013;8(4):e60260. doi: 10.1371/journal.pone.0060260. Epub 2013 Apr 5.

14.

Chronic obstructive pulmonary disease.

Vijayan VK.

Indian J Med Res. 2013 Feb;137(2):251-69. Review.

15.

Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality.

Burgel PR, Paillasseur JL, Peene B, Dusser D, Roche N, Coolen J, Troosters T, Decramer M, Janssens W.

PLoS One. 2012;7(12):e51048. doi: 10.1371/journal.pone.0051048. Epub 2012 Dec 7.

16.

Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency.

Kim V, Kretschman DM, Sternberg AL, DeCamp MM Jr, Criner GJ; National Emphysema Treatment Trial Research Group.

Am J Respir Crit Care Med. 2012 Dec 1;186(11):1109-16. doi: 10.1164/rccm.201203-0538OC. Epub 2012 Aug 9.

17.

Unplanned adaptations before breaking the blind.

Posch M, Proschan MA.

Stat Med. 2012 Dec 30;31(30):4146-53. doi: 10.1002/sim.5361. Epub 2012 Jun 27.

18.

Current status of immunotherapy for the treatment of lung cancer.

Murala S, Alli V, Kreisel D, Gelman AE, Krupnick AS.

J Thorac Dis. 2010 Dec;2(4):237-44. doi: 10.3978/j.issn.2072-1439.2010.11.6.

19.

Several clinical interests regarding lung volume reduction surgery for severe emphysema: meta-analysis and systematic review of randomized controlled trials.

Huang W, Wang WR, Deng B, Tan YQ, Jiang GY, Zhou HJ, He Y.

J Cardiothorac Surg. 2011 Nov 10;6:148. doi: 10.1186/1749-8090-6-148. Review.

20.

Prediction of cardiovascular events by using non-vascular findings on routine chest CT.

de Jong PA, Gondrie MJ, Buckens CF, Jacobs PC, Mali WP, van der Graaf Y; PROVIDI study group.

PLoS One. 2011;6(10):e26036. doi: 10.1371/journal.pone.0026036. Epub 2011 Oct 12.

Supplemental Content

Support Center